Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Trial Profile

Randomised, double blind, multicentre, placebo controlled phase III study of the safety and tolerability following administration of live attenuated JE [Japanese encephalitis] vaccine (ChimeriVax-JE)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi Pasteur Holding
  • Most Recent Events

    • 08 Jul 2011 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12605000575639).
    • 26 Jan 2009 Actual end date (Nov 2006) added as reported by ClinicalTrials.gov.
    • 26 Jan 2009 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top